Focusing on ALL in the CNS, recent data from animal models show the therapeutical effects of CXCR4 antagonists [131,270], the anti-VEGF antibody bevacizumab [128] as well as a monoclonal antibody to integrin α6 [130]. This evidence concerns the gene CXCR4 and acute lymphoblastic leukemia.